Aimee K. Bence

698 total citations
21 papers, 591 citations indexed

About

Aimee K. Bence is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Aimee K. Bence has authored 21 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Aimee K. Bence's work include DNA Repair Mechanisms (5 papers), Polyamine Metabolism and Applications (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Aimee K. Bence is often cited by papers focused on DNA Repair Mechanisms (5 papers), Polyamine Metabolism and Applications (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Aimee K. Bence collaborates with scholars based in United States, Czechia and Spain. Aimee K. Bence's co-authors include Peter A. Crooks, Fei Shen, Leonard C. Erickson, Barbara J. Bailey, William T. Beck, Shaoyou Chu, David R. Worthen, Val R. Adams, Marshall H. Montrose and James P. Stables and has published in prestigious journals such as Cancer Research, Brain Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Aimee K. Bence

21 papers receiving 570 citations

Peers

Countries citing papers authored by Aimee K. Bence

Since Specialization

Citations

This map shows the geographic impact of Aimee K. Bence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimee K. Bence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimee K. Bence more than expected).

Fields of papers citing papers by Aimee K. Bence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimee K. Bence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimee K. Bence. The network helps show where Aimee K. Bence may publish in the future.

Co-authorship network of co-authors of Aimee K. Bence

This figure shows the co-authorship network connecting the top 25 collaborators of Aimee K. Bence. A scholar is included among the top collaborators of Aimee K. Bence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimee K. Bence. Aimee K. Bence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors. 2013 ·Cancer Research ·Johanna C. Bendell, Filip Jankú, Jeffrey R. Infante, Suzanne F. Jones, Howard A. Burris, (unknown), Scott M. Hynes, Ji Lin, Aimee K. Bence, (unknown), Razelle Kurzrock, David S. Hong	1
2	Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors. 2011 ·Molecular Cancer Therapeutics ·Victoria L. Peek, Suzane L. Um, S. Betty Yan, Lei Yan, Jack Dempsey, Darlene Barnard, (unknown), Darryl Ballard, Kathleen M. Heinz-Taheny, Mark S. Marshall, Richard P. Beckmann, Aimee K. Bence, Eric H. Westin	1
3	Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer. 2011 ·Molecular Cancer Therapeutics ·Emiliano Calvo, Donald Richards, Fadi Braiteh, Daniel D. Von Hoff, Robert R. McWilliams, Carlos Becerra, Matthew D. Galsky, Gayle Jameson, Karla Hurt, Scott M. Hynes, Ignacio Garcia‐Ribas, Aimee K. Bence, Eric H. Westin	2
4	Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents. 2011 ·Molecular Cancer Therapeutics ·Samuel McNeely, Teresa F. Burke, (unknown), Darlene Barnard, Mark S. Marshall, Aimee K. Bence, Richard P. Beckmann	6
5	194 Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor 2010 ·European Journal of Cancer Supplements ·Mhairi Marshall, (unknown), Darlene Barnard, (unknown), David A. Barda, Aimee K. Bence, Eric H. Westin	1
6	In vivo evaluation of diaminodiphenyls: Anticonvulsant agents with minimal acute neurotoxicity 2009 ·Bioorganic & Medicinal Chemistry Letters ·David R. Worthen, Aimee K. Bence, James P. Stables, Peter A. Crooks	4
7	Dynamic Assessment of Mitoxantrone Resistance and Modulation of Multidrug Resistance by Valspodar (PSC833) in Multidrug Resistance Human Cancer Cells 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Fei Shen, Barbara J. Bailey, Shaoyou Chu, Aimee K. Bence, (unknown), (unknown), Ahmad R. Safa, William T. Beck, Leonard C. Erickson	33
8	Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Fei Shen, Shaoyou Chu, Aimee K. Bence, Barbara J. Bailey, (unknown), (unknown), Marshall H. Montrose, William T. Beck, Leonard C. Erickson	234
9	Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects 2004 ·Investigational New Drugs ·Aimee K. Bence, (unknown), (unknown), Michael Doukas, (unknown), George A. Davis, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, (unknown), Carolyn J. Bowen, Neil L. Spector, Showchien Hsieh, Val R. Adams	98
10	Evaluation of mitoxantrone accumulation and multidrug resistance transporters in prostate cancer cells 2004 ·Aimee K. Bence, Fei Shen, Leonard C. Erickson	6
11	The Mechanism of l-Canavanine Cytotoxicity: Arginyl tRNA Synthetase as a Novel Target for Anticancer Drug Discovery 2003 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Aimee K. Bence, Peter A. Crooks	40
12	An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine 2003 ·Pharmacology Biochemistry and Behavior ·Aimee K. Bence, David R. Worthen, James P. Stables, Peter A. Crooks	62
13	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells. 2003 ·PubMed ·Aimee K. Bence, Val R. Adams, Peter A. Crooks	19
14	L-Canavanine as a radiosensitization agent for human pancreatic cancer cells 2003 ·Molecular and Cellular Biochemistry ·Aimee K. Bence, Val R. Adams, Peter A. Crooks	15
15	Pegfilgrastim: A New Therapy to Prevent Neutropenic Fever 2002 ·Journal of the American Pharmaceutical Association (1996) ·Aimee K. Bence, Val R. Adams, Peggy Piascik	5
16	SYNTHESIS OFL-INDOSPICINE 2002 ·Synthetic Communications ·Aimee K. Bence, Peter A. Crooks	8
17	The antiproliferative and immunotoxic effects of L-canavanine and L-canaline 2002 ·Anti-Cancer Drugs ·Aimee K. Bence, David R. Worthen, Val R. Adams, Peter A. Crooks	28
18	Endogenous indoles as novel polyamine site ligands at the N-methyl-d-aspartate receptor complex 2001 ·Brain Research ·David R. Worthen, D. Alex Gibson, Dennis T. Rogers, Aimee K. Bence, (unknown), John M. Littleton, Peter A. Crooks	11
19	Aminoanthraquinones as novel ligands at the polyamine binding site on the N-methyl-d-aspartate receptor complex 2000 ·Bioorganic & Medicinal Chemistry Letters ·Aimee K. Bence, Dennis T. Rogers, David R. Worthen, (unknown), John M. Littleton, Peter A. Crooks	8
20	Dapsone analogs as potential polyamine binding site modulators of the N‐methyl‐D‐aspartate receptor complex 2000 ·Drug Development Research ·Aimee K. Bence, Dennis T. Rogers, David R. Worthen, (unknown), John M. Littleton, Peter A. Crooks	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact